Back to Search Start Over

Current acetylcholinesterase-inhibitors: a neuroinformatics perspective.

Authors :
Shaikh S
Verma A
Siddiqui S
Ahmad SS
Rizvi SM
Shakil S
Biswas D
Singh D
Siddiqui MH
Shakil S
Tabrez S
Kamal MA
Source :
CNS & neurological disorders drug targets [CNS Neurol Disord Drug Targets] 2014 Apr; Vol. 13 (3), pp. 391-401.
Publication Year :
2014

Abstract

This review presents a concise update on the inhibitors of the neuroenzyme, acetylcholinesterase (AChE; EC 3.1.1.7). AChE is a serine protease, which hydrolyses the neurotransmitter, acetylcholine into acetate and choline thereby terminating neurotransmission. Molecular interactions (mode of binding to the target enzyme), clinical applications and limitations have been summarized for each of the inhibitors discussed. Traditional inhibitors (e.g. physostigmine, tacrine, donepezil, rivastigmine etc.) as well as novel inhibitors like various physostigmine-derivatives have been covered. This is followed by a short glimpse on inhibitors derived from nature (e.g. Huperzine A and B, Galangin). Also, a discussion on 'hybrid of pre-existing drugs' has been incorporated. Furthermore, current status of therapeutic applications of AChEinhibitors has also been summarized.

Details

Language :
English
ISSN :
1996-3181
Volume :
13
Issue :
3
Database :
MEDLINE
Journal :
CNS & neurological disorders drug targets
Publication Type :
Academic Journal
Accession number :
24059296
Full Text :
https://doi.org/10.2174/18715273113126660166